← All trials
NCT07275645
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2025
- Primary completion
- Feb 18, 2026
- Completion date
- Feb 18, 2027
- First posted
- Dec 10, 2025
- Last posted
- Dec 18, 2025
- Enrollment
- 3000
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ab&b Biotechnology Co., Ltd.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.